Trial reportJournal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine2009
Effect of ramelteon on middle-of-the-night balance in older adults with chronic insomnia.
Trial report in Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00568789 (A Study of the Safety of Ramelteon in Elderly Subjects), which is not on this map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Study of the Safety of Ramelteon in Elderly Subjects
Who cites it
23 citing papers in PubMed.
- Nighttime safety of daridorexant: Evaluation of responsiveness to an external noise stimulus, postural stability, walking, and cognitive function.Journal of psychopharmacology (Oxford, England) · 2025Trial
- The interactive walkway provides fit-for-purpose fall-risk biomarkers in the elderly: Comparison of zolpidem and suvorexant.Clinical and translational science · 2024Trial
- Safety of lemborexant versus placebo and zolpidem: effects on auditory awakening threshold, postural stability, and cognitive performance in healthy older participants in the middle of the night and upon morning awakening.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2020Trial
- Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2017Trial
- The effects of acute treatment with ramelteon, triazolam, and placebo on driving performance, cognitive function, and equilibrium function in healthy volunteers.Psychopharmacology · 2015Trial
- Trial
- Ramelteon prior to a short evening nap impairs neurobehavioral performance for up to 12 hours after awakening.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2010Trial
- Acute and chronic zolpidem administration changes hippocampal long-term potentiation (LTP) as a possible mechanism of memory impairment.Iranian journal of basic medical sciences · 2026Article
- Dual orexin receptor antagonists as promising therapeutics for Alzheimer's disease.Npj biological timing and sleep · 2025Review
- Geriatric Emergency Medication Safety Recommendations (GEMS-Rx): Modified Delphi Development of a High-Risk Prescription List for Older Emergency Department Patients.Annals of emergency medicine · 2024Article
- 2023 Guidelines on the Diagnosis and Treatment of Insomnia in Adults - Brazilian Sleep Association.Sleep science (Sao Paulo, Brazil) · 2023Review
- Association between nocturnal falls and hypnotic drug use in older patients at acute care hospitals.European journal of clinical pharmacology · 2023Article
- Combined Effects of Having Sleep Problems and Taking Sleeping Pills on the Skeletal Muscle Mass and Performance of Community-Dwelling Elders.Scientific reports · 2019Article
- Insomnia in Elderly Patients: Recommendations for Pharmacological Management.Drugs & aging · 2018Review
- Insomnia in the Elderly: A Review.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2018Review
- Sleep in older adults: normative changes, sleep disorders, and treatment options.Clinics in geriatric medicine · 2014Review
- Middle-of-the-night hypnotic use in a large national health plan.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2013Article
- Therapeutic efficacy and anti-inflammatory effect of ramelteon in patients with insomnia associated with lower urinary tract symptoms.Research and reports in urology · 2013Article
- Pharmacotherapy of insomnia with ramelteon: safety, efficacy and clinical applications.Journal of central nervous system disease · 2011Article
- Critical appraisal of ramelteon in the treatment of insomnia.Nature and science of sleep · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
STUDY
objectivesTo evaluate the effect of ramelteon on middle-of-the-night balance, mobility, and memory in older insomniacs.
methodsThirty-three older adults (age > or = 65 years) with insomnia were enrolled in a single-dose, 3-way crossover study of balance after bedtime administration of ramelteon, 8 mg; zolpidem, 10 mg (positive control); or placebo. Subjects were administered study medication 30 minutes before bedtime and were awakened 2 hours after dosing to evaluate balance (Sensory Organization Test), turning speed and stability, memory (immediate and delayed word recall), and adverse events. There was a 4- to 10-day washout between treatments.
resultsRamelteon or zolpidem (positive control) was compared with placebo. There were no differences between placebo and ramelteon on the Sensory Organization Test (p = 0.837), turn time (p = 0.776), or turn sway (p = 0.982). The positive control (zolpidem) did reveal significant impairments on the Sensory Organization Test, turn time, and turn sway (p < 0.001, all). Immediate and delayed memory recall were not significantly different with ramelteon (p = 0.683 and p = 0.650, respectively). Immediate recall declined significantly with zolpidem (p = 0.002). Adverse events were infrequent (ramelteon, n = 7; placebo, n = 7; zolpidem, n = 13); none were serious.
conclusionIn older adults, ramelteon did not impair middle-of-the night balance, mobility, or memory relative to placebo.
Indexed as
Identifiers
19317379PMC2637164What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.